Zacks: Analysts Anticipate UroGen Pharma Ltd. (NASDAQ:URGN) to Announce -$1.26 EPS

Equities analysts expect UroGen Pharma Ltd. (NASDAQ:URGN) to announce ($1.26) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for UroGen Pharma’s earnings. The highest EPS estimate is ($1.10) and the lowest is ($1.36). UroGen Pharma reported earnings per share of ($1.31) in the same quarter last year, which suggests a positive year-over-year growth rate of 3.8%. The company is scheduled to report its next earnings results on Monday, November 8th.

According to Zacks, analysts expect that UroGen Pharma will report full year earnings of ($4.90) per share for the current year, with EPS estimates ranging from ($5.11) to ($4.52). For the next year, analysts forecast that the business will post earnings of ($3.29) per share, with EPS estimates ranging from ($4.28) to ($1.61). Zacks’ EPS averages are an average based on a survey of analysts that follow UroGen Pharma.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, August 4th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.07). UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. The business had revenue of $13.03 million for the quarter, compared to analyst estimates of $13.00 million.

Separately, Zacks Investment Research lowered UroGen Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, July 20th.

NASDAQ:URGN traded up $0.29 during mid-day trading on Friday, hitting $15.43. 549 shares of the company’s stock traded hands, compared to its average volume of 160,216. The company has a fifty day moving average of $15.73 and a 200 day moving average of $17.39. UroGen Pharma has a twelve month low of $14.19 and a twelve month high of $28.20. The company has a market capitalization of $322.49 million, a P/E ratio of -3.01 and a beta of 1.22.

A number of institutional investors have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC grew its holdings in UroGen Pharma by 343.7% during the second quarter. Parametric Portfolio Associates LLC now owns 65,179 shares of the company’s stock worth $995,000 after acquiring an additional 50,489 shares during the period. Morgan Stanley grew its holdings in UroGen Pharma by 5,869.2% during the second quarter. Morgan Stanley now owns 73,600 shares of the company’s stock worth $1,125,000 after acquiring an additional 72,367 shares during the period. Meitav Dash Investments Ltd. grew its holdings in UroGen Pharma by 58.8% during the second quarter. Meitav Dash Investments Ltd. now owns 100,519 shares of the company’s stock worth $1,535,000 after acquiring an additional 37,239 shares during the period. Wells Fargo & Company MN grew its holdings in UroGen Pharma by 368.3% during the second quarter. Wells Fargo & Company MN now owns 19,916 shares of the company’s stock worth $304,000 after acquiring an additional 15,663 shares during the period. Finally, Zeke Capital Advisors LLC grew its holdings in UroGen Pharma by 39.8% during the second quarter. Zeke Capital Advisors LLC now owns 722,875 shares of the company’s stock worth $11,038,000 after acquiring an additional 205,769 shares during the period.

UroGen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.

Read More: What is a blue-chip stock?

Get a free copy of the Zacks research report on UroGen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.